West Pharmaceutical Services (WST) Long-Term Investments (2009 - 2026)

West Pharmaceutical Services (WST) has reported Long-Term Investments for 18 consecutive years, with $207.7 million the latest figure, recorded in Q2 2026.

• Quarterly Long-Term Investments fell 7.57% year-over-year to $207.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $207.7 million (down 7.57% YoY) and the FY2025 annual result came in at $212.3 million, up 5.05% from the prior year.
• Long-Term Investments eased to $207.7 million in Q2 2026 per WST's latest filing, from $209.2 million in the prior quarter.
• Over the last five years, Long-Term Investments for WST reached as high as $224.7 million in Q2 2025 and fell as low as $188.6 million in Q3 2022.
• A 5-year average of $206.6 million and a median of $207.9 million in 2022 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2022 — Long-Term Investments declined 12.56% — and 2025, when it rose 13.37%.
• Year by year, Long-Term Investments stood at $204.9 million in 2022, then climbed by 2.49% to $210.0 million in 2023, then decreased by 3.76% to $202.1 million in 2024, then advanced by 5.05% to $212.3 million in 2025, then declined by 2.17% to $207.7 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $207.7 million, $209.2 million, and $212.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.